How to evaluate combination therapy using interferon and nucleos(t)ide analogues
Chronic hepatitis B is still one of the most important chronic diseases in China because of its high relevance to liver cirrhosis and hepatic cell cancer (HCC). Currently, interferon and nucleos(t)ide analogues are two main treatments for chronic hepatitis B, but they have advantages and disadvantag...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Department of Journal of Clinical Hepatology
2016-11-01
|
| Series: | Linchuang Gandanbing Zazhi |
| Online Access: | http://www.lcgdbzz.org/qk_content.asp?id=7798 |
| Summary: | Chronic hepatitis B is still one of the most important chronic diseases in China because of its high relevance to liver cirrhosis and hepatic cell cancer (HCC). Currently, interferon and nucleos(t)ide analogues are two main treatments for chronic hepatitis B, but they have advantages and disadvantages. More investigations are needed to explore better ways for treating this disease, and combination therapy might be one of the options. This article analyzes the advances in various combination therapies and points out views about the selection of combination therapies and patients. |
|---|---|
| ISSN: | 1001-5256 1001-5256 |